177 related articles for article (PubMed ID: 24244431)
21. Delphinidin suppresses proliferation and migration of human ovarian clear cell carcinoma cells through blocking AKT and ERK1/2 MAPK signaling pathways.
Lim W; Jeong W; Song G
Mol Cell Endocrinol; 2016 Feb; 422():172-181. PubMed ID: 26704080
[TBL] [Abstract][Full Text] [Related]
22. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
23. CEMIP promotes ovarian cancer development and progression via the PI3K/AKT signaling pathway.
Shen F; Zong ZH; Liu Y; Chen S; Sheng XJ; Zhao Y
Biomed Pharmacother; 2019 Jun; 114():108787. PubMed ID: 30925458
[TBL] [Abstract][Full Text] [Related]
24. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
25. Upregulated microRNA-15b alleviates ovarian cancer through inhitbition of the PI3K/Akt pathway by targeting LPAR3.
Li GC; Qin XL; Song HH; Li YN; Qiu YY; Cui SC; Wang YS; Wang H; Gong JL
J Cell Physiol; 2019 Dec; 234(12):22331-22342. PubMed ID: 31140597
[TBL] [Abstract][Full Text] [Related]
26. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
[TBL] [Abstract][Full Text] [Related]
27. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
28. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.
Noske A; Kaszubiak A; Weichert W; Sers C; Niesporek S; Koch I; Schaefer B; Sehouli J; Dietel M; Lage H; Denkert C
Cancer Lett; 2007 Feb; 246(1-2):190-200. PubMed ID: 16584837
[TBL] [Abstract][Full Text] [Related]
29. ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways.
Wu Y; Tan X; Liu P; Yang Y; Huang Y; Liu X; Meng X; Yu B; Wu M; Jin H
Exp Cell Res; 2019 Jun; 379(1):30-47. PubMed ID: 30894280
[TBL] [Abstract][Full Text] [Related]
30. PtdIns(3,4,5)P3-dependent Rac Exchanger 1 (PREX1) Rac-Guanine Nucleotide Exchange Factor (GEF) Activity Promotes Breast Cancer Cell Proliferation and Tumor Growth via Activation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Signaling.
Liu HJ; Ooms LM; Srijakotre N; Man J; Vieusseux J; Waters JE; Feng Y; Bailey CG; Rasko JE; Price JT; Mitchell CA
J Biol Chem; 2016 Aug; 291(33):17258-70. PubMed ID: 27358402
[TBL] [Abstract][Full Text] [Related]
31. Role of PELP1/MNAR signaling in ovarian tumorigenesis.
Dimple C; Nair SS; Rajhans R; Pitcheswara PR; Liu J; Balasenthil S; Le XF; Burow ME; Auersperg N; Tekmal RR; Broaddus RR; Vadlamudi RK
Cancer Res; 2008 Jun; 68(12):4902-9. PubMed ID: 18559538
[TBL] [Abstract][Full Text] [Related]
32. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
33. Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.
Buchanan PC; Boylan KLM; Walcheck B; Heinze R; Geller MA; Argenta PA; Skubitz APN
J Biol Chem; 2017 Apr; 292(15):6339-6351. PubMed ID: 28232483
[TBL] [Abstract][Full Text] [Related]
34. Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages.
Luyendyk JP; Schabbauer GA; Tencati M; Holscher T; Pawlinski R; Mackman N
J Immunol; 2008 Mar; 180(6):4218-26. PubMed ID: 18322234
[TBL] [Abstract][Full Text] [Related]
35. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
Ma N; Zhao Y
Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
[TBL] [Abstract][Full Text] [Related]
36. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells.
Lau MT; So WK; Leung PC
PLoS One; 2013; 8(3):e59083. PubMed ID: 23554977
[TBL] [Abstract][Full Text] [Related]
37. Effects of Per2 overexpression on growth inhibition and metastasis, and on MTA1, nm23-H1 and the autophagy-associated PI3K/PKB signaling pathway in nude mice xenograft models of ovarian cancer.
Wang Z; Li L; Wang Y
Mol Med Rep; 2016 Jun; 13(6):4561-8. PubMed ID: 27082164
[TBL] [Abstract][Full Text] [Related]
38. Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathways.
Lin Z; Li S; Guo P; Wang L; Zheng L; Yan Z; Chen X; Cheng Z; Yan H; Zheng C; Zhao C
Life Sci; 2019 Feb; 218():197-204. PubMed ID: 30582951
[TBL] [Abstract][Full Text] [Related]
39. Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells.
Reddy P; Liu L; Ren C; Lindgren P; Boman K; Shen Y; Lundin E; Ottander U; Rytinki M; Liu K
Mol Endocrinol; 2005 Oct; 19(10):2564-78. PubMed ID: 15928314
[TBL] [Abstract][Full Text] [Related]
40. High WAVE3 expression correlates with proliferation, migration and invasion in human ovarian cancer.
Lu J; Wang SL; Wang YC; Wu YN; Yu X; Zhao WZ; Wang JH
Oncotarget; 2017 Jun; 8(25):41189-41201. PubMed ID: 28476025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
